骨髓瘤中CD52的表达模式及阿仑单抗治疗的适用性。

CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.

作者信息

Rawstron Andy C, Laycock-Brown Giles, Hale Geoff, Davies Faith E, Morgan Gareth J, Child J Anthony, Hillmen Peter, Owen Roger G

出版信息

Haematologica. 2006 Nov;91(11):1577-8. Epub 2006 Oct 17.

PMID:17043027

Abstract

Alemtuzumab has been proposed as a therapeutic agent in myeloma. CD52 was detected on plasma cells in 46/106 patients but levels were 30-fold lower than on alemtuzumab-responsive cells (n=138) and 8-fold lower than on alemtuzumab-resistant cells (n=57). The data suggest that myeloma plasma cells are unlikely to be depleted by alemtuzumab in most patients.

摘要

阿仑单抗已被提议作为骨髓瘤的一种治疗药物。在106例患者中，有46例的浆细胞检测到CD52，但水平比阿仑单抗反应性细胞（n = 138）低30倍，比阿仑单抗耐药细胞（n = 57）低8倍。数据表明，在大多数患者中，阿仑单抗不太可能使骨髓瘤浆细胞耗竭。